Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.solara.co.in | |
Market Cap | 1,549.28 Cr. | |
Enterprise Value(EV) | 2,526.60 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -16.15 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
Industry PE | 29.26 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 423.63 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 1.02 | Calculated using Price: 430.40 |
Dividend Yield | 1.63 | Period Ending 2021-03 |
No. of Shares Subscribed | 3.60 Cr. | 35,996,267 Shares |
FaceValue | 10 | |
Company Profile | ||
Solara Active Pharma Sciences is a dynamic, entrepreneurial and customer-oriented API manufacturer. It has a legacy of over three decades and trace its origins to the API expertise of Strides Shasun Ltd. and the technical know-how of human API business from Sequent Scientific Ltd. The company is poised to bridge the industry gap by delivering value-based products while maintaining focus on customer needs. It has hundreds of scientists working at its two R&D Centers and many API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities. The company has a highly compliant manufacturing footprint spread over six large scale multi-product facilities. The company’s business is spread across several countries with extensive operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa. Business area of the company The company is a global, R&D focused, pureplay API company engaged in the manufacturing and development of APIs and offering Contract Manufacturing and Development Services for global companies. Products and services
|
1 Day |
|
+0.40% |
1 Week |
|
-3.32% |
1 Month |
|
-39.15% |
3 Month |
|
-44.04% |
6 Month |
|
-58.74% |
1 Year |
|
-75.41% |
2 Year |
|
-6.80% |
5 Year |
|
|
10 Year |
|
4 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 0.04 | 7.36 | 12.48 | 17.23 | |
Return on Capital Employed (%) | 1.82 | 9.70 | 11.73 | 15.34 | |
Return on Assets (%) | 0.02 | 3.14 | 5.57 | 9.34 |
Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
Shh. Funds | 764 | 956 | 1,086 | 1,589 | 1,525 | |
Non Curr. Liab. | 315 | 344 | 333 | 206 | 299 | |
Curr. Liab. | 738 | 656 | 730 | 789 | 1,071 | |
Minority Int. | 4 | 4 | 4 | 4 | 2 | |
Equity & Liab. | 1,821 | 1,960 | 2,153 | 2,588 | 2,897 | |
Non Curr. Assets | 1,214 | 1,312 | 1,481 | 1,530 | 1,658 | |
Curr. Assets | 608 | 648 | 672 | 1,058 | 1,239 | |
Misc. Exp. not W/O | ||||||
Total Assets | 1,821 | 1,960 | 2,153 | 2,588 | 2,897 |
Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
Net Sales | 560 | 1,409 | 1,322 | 1,617 | 1,268 | |
Other Income | 2 | 12 | 28 | 29 | 20 | |
Total Income | 563 | 1,421 | 1,349 | 1,646 | 1,288 | |
Total Expenditure | -501 | -1,197 | -1,062 | -1,231 | -1,188 | |
PBIDT | 62 | 224 | 287 | 415 | 100 | |
Interest | -25 | -82 | -78 | -84 | -75 | |
Depreciation | -37 | -84 | -94 | -109 | -112 | |
Taxation | 0 | 2 | 0 | 0 | 33 | |
Exceptional Items | -3 | |||||
PAT | 0 | 59 | 115 | 221 | -58 | |
Minority Interest | 0 | 0 | 0 | 0 | 0 | |
Share Associate | ||||||
Other Related Items | ||||||
Consolidated Net Profit | 0 | 60 | 115 | 221 | -58 | |
Adjusted EPS | 0 | 23 | 43 | 62 | -16 |
Particulars | 4 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 49 | 166 | 242 | 155 | |
Cash Fr. Inv. | -85 | -116 | -359 | -106 | |
Cash Fr. Finan. | 68 | -23 | 97 | 92 | |
Net Change | 31 | 27 | -20 | 142 | |
Cash & Cash Eqvt | 46 | 76 | 56 | 198 |
Sat, 21 May 2022
Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Karuna Business Solutions LLP |
||||||||||||||||||||||||||||||||||||||||||||||||||
Fri, 13 May 2022
Disclosure Of Related Party Transactions For The Period Ended March 31 2022 Disclosure Of Related Party Transactions For The period Ended March 31 2022 |
||||||||||||||||||||||||||||||||||||||||||||||||||
Fri, 13 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.
Date: 13/05/2022 |
Fri, 20 May 2022 |
|
|
|
|
|